Früherkennung und
Früherkennung und Diagnose von Herz-Kreislauf-Erkrankungen: Ein Manifest für Veränderung 47. Cleveland Clinic. nd. B-type Natriuretic Peptide (BNP) Test. Available from: https://my.clevelandclinic.org/health/ diagnostics/22629-b-type-natriuretic-peptide [Accessed 04/12/2023] 48. Taylor C, Lay-Flurrie S, Ordóñez-Mena J, et al. 2022. Natriuretic peptide level at heart failure diagnosis and risk of hospitalisation and death in England 2004-2018. Heart 108(7): 543-49 49. European Heart Network, European Society of Cardiology. 2020. Fighting cardiovascular disease - a blueprint for EU action. Brussels: European Heart Network 50. Herbert B, Johnson A, Paasche-Orlow M, et al. 2021. Disparities in Reporting a History of Cardiovascular Disease Among Adults With Limited English Proficiency and Angina. JAMA Network Open 4(12): 10.1001/jamanetworkopen.2021.38780 51. Hossain M, Chew-Graham C, Sowden E, et al. 2022. Challenges in the management of people with heart failure with preserved ejection fraction (HFpEF) in primary care: A qualitative study of general practitioner perspectives. Chronic Illness 18(2): 410-25 52. Soljak M, Samarasundera E, Indulkar T, et al. 2011. Variations in cardiovascular disease under-diagnosis in England: national cross-sectional spatial analysis. BMC Cardiovascular Disorders 11: 10.1186/471-2261-11-12 53. Saner H, van der Velde E. 2016. eHealth in cardiovascular medicine: A clinical update. European Journal of Preventive Cardiology 23(2 suppl): 5-12 54. Chiou Y-A, Hung C-L, Lin S-F. 2021. AI-Assisted Echocardiographic Prescreening of Heart Failure With Preserved Ejection Fraction on the Basis of Intrabeat Dynamics. JACC: Cardiovascular Imaging 14(11): 2091-104 55. Muldoon L, Hogg W, Levitt M. 2006. Primary care (PC) and primary health care (PHC). What is the difference? Canadian Journal of Public Health 97(5): 409-11 56. Joshi R, Thrift A, Smith C, et al. 2018. Task-shifting for cardiovascular risk factor management: lessons from the Global Alliance for Chronic Diseases. BMJ Global Health, 3(Suppl 3): 10.1136/bmjgh-2018-001092 57. European Heart Network, European Society of Cardiology, ERA-CVD. 2019. Challenges and opportunities for cardiovascular disease research: Strategic research agenda for cardiovascular diseases (SRA-CVD). Koeln: German Aerospace Center Deutsches Zentrum für Luft und Raumfahrt DRL 58. Van Norman G. 2017. Overcoming the Declining Trends in Innovation and Investment in Cardiovascular Therapeutics: Beyond EROOM’s Law. JACC: Basic to Translational Science 2(5): 613-25 59. Ballreich J, Gross C, Powe N, et al. 2021. Allocation of National Institutes of Health Funding by Disease Category in 2008 and 2019. JAMA Network Open 4(1): 10.1001/jamanetworkopen.2020.34890 60. Stockmann C, Hersh A, Sherwin C, et al. 2014. Alignment of United States funding for cardiovascular disease research with deaths, years of life lost, and hospitalizations. International Journal of Cardiology 172(1): e19-e21 61. National Center for Health Statistics. 2021. Data brief 427. Mortality in the United States, 2020. Maryland: National Center for Health Statistics 62. Centers for Disease Control and Prevention. U.S. cancer statistics breast cancer stat bite. Available from: https://www.cdc. gov/cancer/uscs/about/stat-bites/stat-bite-breast.htm [Accessed 13/02/2024] 63. MacArthur J, Yong G, Dweck M, et al. 2023. Cardiovascular imaging research priorities. Open Heart 10: 10.1136/ openhrt-2023-002378 64. Sweeney T, Quispe R, Das T, et al. 2021. The Use of Blood Biomarkers in Precision Medicine for the Primary Prevention of Atherosclerotic Cardiovascular Disease: a Review. Expert Review of Precision Medicine and Drug Development 6(4): 247-58 65. Isselbacher E, Preventza O, Hamilton Black J, et al. 2022. 2022 ACC/AHA Guideline for the diagnosis and management of aortic disease: A report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation 146(24): e334-e482 66. Arbelo E, Protonotarios A, Gimeno J, et al. 2023. 2023 ESC Guidelines for the management of cardiomyopathies: Developed by the task force on the management of cardiomyopathies of the European Society of Cardiology (ESC) European Heart Journal 44(37): 3503-626 67. Karnad A, Harding E, Farrington-Douglas J, et al. 2022. Making the case for political urgency in cardiovascular disease. Thought Leadership Forum on Cardiovascular Disease discussion paper. London: The Health Policy Partnership 68. Su P-F, Sie F-C, Yang C-T, et al. 2020. Association of ambient air pollution with cardiovascular disease risks in people with type 2 diabetes: a Bayesian spatial survival analysis. Environmental Health 19(1): 10.1186/s12940-020-00664-0 28
GLOBAL HEART HUB 69. European Society of Cardiology. 2021. Closing the gaps in the cardiovascular care of women. Sophia Antipolis: European Society of Cardiology 70. Daponte-Codina A, Knox E, Mateo-Rodriguez I, et al. 2022. Gender and social inequalities in awareness of coronary artery disease in European countries. International Journal of Environmental Research and Public Health 19(3): 10.3390/ ijerph19031388 71. Daugherty S, Blair I, Havranek E, et al. 2017. Implicit gender bias and the use of cardiovascular tests among cardiologists. Journal of the American Heart Association 6(12): 10.1161/JAHA.117.006872 72. Anagnostis P, Lambrinoudaki I, Stevenson J, et al. 2022. Menopause-associated risk of cardiovascular disease. Endocrine Connections 11(4): 10.1530/EC-21-0537 73. Mullachery P, Vela E, Cleries M, et al. 2022. Inequalities by income in the prevalence of cardiovascular disease and its risk factors in the adult population of Catalonia. Journal of the American Heart Association 11(17): 10.1161/JAHA.122.026587 74. Niakouei A, Tehrani M, Fulton L. 2020. Health Disparities and Cardiovascular Disease. Healthcare (Basel) 8(1): 10.3390/ healthcare8010065 75. Stoner L, Stoner K, Young J, et al. 2012. Preventing a cardiovascular disease epidemic among indigenous populations through lifestyle changes. International Journal of Preventative Medicine 3(4): 230-40 76. Holman D, Salway S, Bell A, et al. 2021. Can intersectionality help with understanding and tackling health inequalities? Perspectives of professional stakeholders. Health Research Policy and Systems 19(1): 10.1186/s12961-021-00742-w 77. Post W, Watson K, Hansen S, et al. 2022. Racial and Ethnic Differences in All-Cause and Cardiovascular Disease Mortality: The MESA Study. Circulation 146(3): 229-39 78. International Longevity Centre UK. 2024. Holding us back? Tackling inequalities in the detection and treatment of structural heart disease in Europe. London: International Longevity Centre UK 79. Ahmed Y, van Bakel P, Hou H, et al. 2023. Racial and ethnic disparities in diagnosis, management and outcomes of aortic stenosis in the Medicare population. PLoS One 18(4): 10.1371/journal.pone.0281811 80. World Health Organization. 2010 Global status report on noncommunicable diseases. Gevena: World Health Organization 81. Wurie H, Capuccio F. 2012. Cardiovascular disease in low- and middle-income countries: an urgent priority. Ethnicity & Health 17(6): 543-50 82. Minja N, Nakagaayi D, Aliku T, et al. 2022. Cardiovascular diseases in Africa in the twenty-first century: Gaps and priorities going forward. Frontiers in Cardiovascular Medicine 9: 10.3389/fcvm.2022.1008335 29
